Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 11/20 | 0.62 |
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626224 | 0.92 | MAP3K14 (0.73) | MAP3K14CHUKKDM1A | |
| SCHEMBL19626230 | 0.87 | MAP3K14 (0.61) | MAP3K14CHUKKDM1A | |
| SCHEMBL19626214 | 0.85 | MAP3K14 (0.63) | MAP3K14CHUKKDM1A | |
| SCHEMBL19626226 | 0.84 | MAP3K14 (0.55) | MAP3K14CHUKKDM1A | |
| SCHEMBL19626233 | 0.82 | MAP3K14 (0.62) | MAP3K14CHUKKDM1A | |
| SCHEMBL19626231 | 0.80 | MAP3K14 (0.59) | MAP3K14CHUK | |
| SCHEMBL19626227 | 0.80 | MAP3K14 (0.57) | MAP3K14CHUK | |
| SCHEMBL19626247 | 0.79 | MAP3K14 (0.52) | MAP3K14CHUKKDM1A | |
| SCHEMBL19626232 | 0.79 | MAP3K14 (0.56) | MAP3K14CHUK | |
| SCHEMBL19626217 | 0.78 | MAP3K14 (0.46) | MAP3K14CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | MAP3K14 1/4885CHUK 32/4885KDM1A 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.